Evidence map›Paper›PMID 40088122›Full record

ArticleEuropean journal of haematology2025

Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis.

Pongthep Vittayawacharin, Benjamin J Lee, Ghayda' E'leimat, Yen Cao, Jack Reid, Ashley Gamayo, Sherif Rezk, Elizabeth A Brem, Lisa X Lee, Piyanuch Kongtim and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pongthep VittayawacharinHematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, California, USA.ORCID https://orcid.org/0000-0002-1131-5564
Benjamin J LeeDepartment of Pharmacy, University of California Irvine Health, Orange, California, USA.ORCID https://orcid.org/0000-0002-1678-1345
Ghayda' E'leimatHematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, California, USA.
Yen CaoDivision of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, California, USA.
Jack ReidDepartment of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, USA.
Ashley GamayoDepartment of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, USA.
Sherif RezkDepartment of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, USA.
Elizabeth A BremDivision of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, California, USA.
Lisa X LeeDivision of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, California, USA.
Piyanuch KongtimHematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, California, USA.
Stefan O CiureaHematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, California, USA.

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

backgroundData on bone marrow (BM) findings in secondary hemophagocytic lymphohistiocytosis (sHLH) and their association with overall survival (OS) are limited.

objectivesThis study aimed to develop a prognostic model incorporating BM findings and clinico-laboratory factors affecting OS.

methodsWe retrospectively evaluated 50 adults with sHLH and developed a clinicopathological prognostic model based on survival-associated factors.

resultsMost patients demonstrated normocellular BM (46.3%) and mild hemophagocytic activity (44.2%). Factors associated with survival in multivariable analyses (MVA) were age above 70 years (hazard ratio [HR] 3.89, p = 0.016), infection-related (HR 4.62, p = 0.006), hemoglobin < 7 g/dL (HR 5.21, p < 0.001), and hypocellular marrow (HR 3.07, p = 0.04). A clinicopathological HLH risk model assigned 1 point to each MVA-identified survival factor, categorizing patients into low- (score 0-1), intermediate- (score 2-3), and high-risk (score 4) groups. The 6-month OS from bootstrapping internal validation among the low-, intermediate-, and high-risk groups were 84.2%, 55.6% (p < 0.001) and 7.7% (p < 0.001), respectively. The area under the receiver operating characteristic curve (AuROC) was 0.87.

conclusionsThis model stratified sHLH patients into three risk groups with distinct survival outcomes, potentially guiding future therapy.

Indexed as

Lymphohistiocytosis, HemophagocyticAdultAgedAged, 80 and overBone MarrowFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsROC Curvehemophagocytic lymphohistiocytosishemophagocytosisprognostic modelsurvival

Identifiers

PMID40088122
PMCPMC12571457

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.